Brugada syndrome (BrS) was first described in 1992 as an aberrant pattern of ST segment elevation in right precordial leads with a high incidence of sudden cardiac death (SCD) in patients with structurally normal heart. It represents 4% ∼ 12% of all SCD and 20% of SCD in patients with structurally normal heart. The extremely wide genetic heterogeneity of BrS and other inherited cardiac disorders makes this new area of genetic arrhytmology a fascinating one. This review shows the state of art in diagnosis, management, and treatment of BrS focusing all the aspects regarding genetics and Preimplant Genetic Diagnosis (PGD) of embryos, overlapping syndromes, risk stratification, familial screening, and future perspectives. Moreover the review analyzes key points like electrocardiogram (ECG) criteria, the role of electrophysiological study (the role of ventricular programmed stimulation and the need of universal accepted protocol) and the importance of a correct risk stratification to clarify when implantable cardioverter defibrillator or a close follow-up is needed. In recent years, cardiovascular studies have been focused on personalized risk assessment and to determine the most optimal therapy for an individual. The BrS syndrome has also benefited of these advances although there remain several key points to be elucidated. We will review the present knowledge, progress made, and future research directions on BrS.
Coppola G., Corrado E., Antonio C., Giampiero M., Domenico O., Antonino M., et al. (2019). Update on Brugada Syndrome 2019. CURRENT PROBLEMS IN CARDIOLOGY, 100454.
|Data di pubblicazione:||2019|
|Titolo:||Update on Brugada Syndrome 2019|
COPPOLA, Giuseppe (Corresponding)
|Citazione:||Coppola G., Corrado E., Antonio C., Giampiero M., Domenico O., Antonino M., et al. (2019). Update on Brugada Syndrome 2019. CURRENT PROBLEMS IN CARDIOLOGY, 100454.|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.cpcardiol.2019.100454|
|Appare nelle tipologie:||1.01 Articolo in rivista|